Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola,Antimicrobial Agents and Chemotherapy

当前位置： X-MOL 学术 › Antimicrob. Agents Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola
Antimicrobial Agents and Chemotherapy ( IF 4.9 ) Pub Date : 2021-07-12 , DOI: 10.1128/aac.01117-21
Victoria C Yan ₁ , Florian L Muller ₂

Affiliation

Remdesivir is a nucleoside monophosphoramidate prodrug that has been FDA-approved for COVID-19. However, the clinical efficacy of remdesivir for COVID-19 remains contentious, as several trials have not found statistically significant differences in either ...

中文翻译：

为什么瑞德西韦失败：临床前假设高估了瑞德西韦对 COVID-19 和埃博拉的临床疗效

瑞德西韦是一种核苷单磷酰胺前药，已获得 FDA 批准用于 COVID-19。然而，remdesivir 对 COVID-19 的临床疗效仍然存在争议，因为几项试验没有发现两者在统计学上的显着差异......

更新日期：2021-09-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>